While bacteriophage therapy shows potential, it comes with its set of challenges and considerations. One major hurdle is the need for a precise match between the phage and the targeted bacterial strain. The specificity of bacteriophages can limit their broad-spectrum applicability, requiring a tailored approach for each infection. Additionally, concerns about the rapid development of bacterial resistance to phages and the potential for the immune system to neutralize phages pose challenges to their therapeutic use. Regulatory aspects of phage therapy also warrant attention. Standardizing phage preparations, ensuring their safety, and navigating regulatory frameworks for approval are critical steps in integrating phage therapy into mainstream medical practice. Collaboration between researchers, clinicians, and regulatory agencies is essential for establishing guidelines and protocols that ensure the efficacy and safety of bacteriophage-based treatments. Despite these challenges, ongoing research and clinical trials are advancing our understanding of bacteriophages and their therapeutic potential. As the field continues to evolve, bacteriophage therapy may emerge as a valuable tool in the fight against bacterial infections, offering tailored and sustainable solutions in the era of antibiotic resistance.